
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort Inc. demonstrated an improvement in financial performance, highlighted by an operating margin of (23.4%), which reflects a significant increase of 1,210 basis points year-over-year, surpassing consensus expectations. The company's revenue reached $59.5 million, marking a growth of 4.2% on a constant currency basis, supported by a notable increase in commercial revenue of 37% year-over-year. Additionally, the Life Sciences Products segment reported $20 million in revenue, improving from a prior decline to exceed consensus estimates, further reinforcing a positive outlook as the commercialization of cell and gene therapies is anticipated to drive future revenue growth.
Bears say
CryoPort Inc. has demonstrated a deceleration in revenue growth across its BioLogistics Solutions and BioStorage/BioServices segments, with overall Life Sciences Services revenue growth declining from 9% to 7% in the recent quarter. The company faces significant challenges due to anticipated slower cell and gene therapy approvals, which are expected to negatively impact its margins and profitability. Additionally, increased competition in the cold-chain logistics market further undermines the attractiveness of CryoPort's fundamentals, contributing to a negative outlook on the stock.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares